Page last updated: 2024-11-13

gsk1210151a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

GSK1210151A: inhibitor of the BET family of proteins; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID52912189
CHEMBL ID2017291
CHEBI ID95083
SCHEMBL ID1906755
MeSH IDM0569198

Synonyms (51)

Synonym
HY-13235
i-bet151
SCHEMBL1906755
1gh ,
7-(3,5-dimethyl-1,2-oxazol-4-yl)-8-methoxy-1-[(1r)-1-(pyridin-2-yl)ethyl]-1h,2h,3h-imidazo[4,5-c]quinolin-2-one
bdbm50380682
gsk1210151a
CHEMBL2017291 ,
AKOS016004407
1300031-49-5
BCP9000734
gsk1210151a/i-bet 151
BCP0726000180
NCGC00344588-01
i-bet-151
CS-0930
S2780
7-(3,5-dimethyl-4-isoxazolyl)-1,3-dihydro-8-methoxy-1-[(1r)-1-(2-pyridinyl)ethyl]-2h-imidazo[4,5-c]quinolin-2-one
VUVUVNZRUGEAHB-CYBMUJFWSA-N ,
7-(3,5-dimethyl-4-isoxazolyl)-8-(methyloxy)-1-[(1r)-1-(2-pyridinyl)ethyl]-1,3-dihydro-2h-imidazo[4,5-c]quinolin-2-one
smr004702951
MLS006011182
4ALG
3ZYU
7-(dimethyl-1,2-oxazol-4-yl)-8-methoxy-1-[(1r)-1-(pyridin-2-yl)ethyl]-1h,2h,3h-imidazo[4,5-c]quinolin-2-one
gtpl7518
i-bet 151
7-(3,5-dimethylisoxazol-4-yl)-8-methoxy-1-((r)-1-(pyridin-2-yl)ethyl)-1h-imidazo[4,5-c]quinolin-2(3h)-one
i-bet151 (gsk1210151a)
AC-27406
J-519026
7-(3,5-dimethyl-1,2-oxazol-4-yl)-8-methoxy-1-[(1r)-1-(pyridin-2-yl)ethyl]-1,3-dihydro-2h-imidazo[4,5-c]quinolin-2-one
DTXSID10680599
7-(3,5-dimethyl-4-isoxazolyl)-1,3-dihydro-8-methoxy-1-[(1r)-1-(2-pyridinyl)ethyl]-2h-imidazo[4,5-c]q
(r)-7-(3,5-dimethylisoxazol-4-yl)-8-methoxy-1-(1-(pyridin-2-yl)ethyl)-1,3-dihydro-2h-imidazo[4,5-c]quinolin-2-one
CHEBI:95083
7-(3,5-dimethyl-1,2-oxazol-4-yl)-8-methoxy-1-[(1r)-1-pyridin-2-ylethyl]-3h-imidazo[4,5-c]quinolin-2-one
(r)-7-(3,5-dimethyl isoxazol-4-yl)-8-methoxy-1-(1-(pyridin-2-yl)ethyl)-1,3-dihydro-2h-imidazo[4,5-c]quinolin-2-one
NCGC00344588-08
SW219264-1
BCP03612
mfcd22124472
EX-A1561
Q27078015
2h-imidazo[4,5-c]quinolin-2-one, 7-(3,5-dimethyl-4-isoxazolyl)-1,3-dihydro-8-methoxy-1-[(1r)-1-(2-pyridinyl)ethyl]-
NCGC00344588-15
C72196
gsk1210151a (i-bet151)
NCGC00344588-04
nsc-767599
nsc767599

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
" Inhibition of BET protein expression, in combination with the use of chemotherapeutic drugs such as paclitaxel and cisplatin, further restrained NSCLC cell growth in a synergistic manner."( BET inhibitors combined with chemotherapy synergistically inhibit the growth of NSCLC cells.
Chen, J; Cheng, Z; Luo, J; Meng, Y; Sun, T; Wang, X; Xia, B; Zhang, Z; Zhou, X, 2021
)
0.62

Bioavailability

ExcerptReferenceRelevance
" One member, I-BET151 (GSK1210151A), shows good oral bioavailability in both the rat and minipig as well as demonstrating efficient suppression of bacterial induced inflammation and sepsis in a murine in vivo endotoxaemia model."( Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).
Bamborough, P; Beinke, S; Bouillot, A; Chung, CW; Cutler, L; Donche, F; Gellibert, F; Gordon, L; Kirilovsky, J; Krysa, G; Lamotte, Y; Lee, K; Lewis, T; Lugo, D; McCleary, S; Mirguet, O; Nicodeme, E; Prinjha, RK; Rioja, I; Seal, J; Walker, AL; Wilson, DM; Witherington, J, 2012
)
0.9
"Cell membrane permeability is an important determinant for oral absorption and bioavailability of a drug molecule."( Highly predictive and interpretable models for PAMPA permeability.
Jadhav, A; Kerns, E; Nguyen, K; Shah, P; Sun, H; Xu, X; Yan, Z; Yu, KR, 2017
)
0.46
"We have designed and synthesized 9H-pyrimido[4,5-b]indole-containing compounds to obtain potent and orally bioavailable BET inhibitors."( Structure-Based Discovery of 4-(6-Methoxy-2-methyl-4-(quinolin-4-yl)-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole (CD161) as a Potent and Orally Bioavailable BET Bromodomain Inhibitor.
Bai, L; Hu, Y; Li, S; Li, X; Liu, L; McEachern, D; Meagher, JL; Ran, X; Stuckey, JA; Sun, D; Wang, S; Wen, B; Yang, CY; Zhao, T; Zhao, Y; Zhou, B, 2017
)
0.46
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" Individually increasing or decreasing the expression of these transcription factors suppressed AML cell growth, providing evidence that leukaemia cells are sensitive to the dosage of SE-associated genes."( Mediator kinase inhibition further activates super-enhancer-associated genes in AML.
Arefolov, A; Armstrong, SA; Banka, D; Bronson, RT; Caruso, BT; Christie, AL; Da Silva, DH; Du, K; Ebmeier, CC; Fadeyi, O; Jestel, A; Kohl, NE; Krivtsov, AV; Kung, AL; Lemieux, ME; Liau, BB; Myers, AG; Nitulescu, II; Pelish, HE; Poss, ZC; Schneider, EV; Shair, MD; Si, C; Taatjes, DJ; Tangpeerachaikul, A; Zou, G, 2015
)
0.42
" To experimentally validate this hypothesis, we tested a small-molecule inhibitor of the BET family of proteins, GSK1210151A (I-BET151), in the STAM mouse NASH model at two different dosing timepoints (onset of NASH and progression to fibrosis)."( BET Inhibition Improves NASH and Liver Fibrosis.
Agarwal, P; Cutler, L; Kumar, V; Mander, P; Middleton, SA; Prinjha, RK; Rajpal, D; Rajpal, N; Rioja, I, 2018
)
0.69
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
imidazoquinoline
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (15)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
PPM1D proteinHomo sapiens (human)Potency2.94110.00529.466132.9993AID1347411
EWS/FLI fusion proteinHomo sapiens (human)Potency8.66140.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
Interferon betaHomo sapiens (human)Potency2.94110.00339.158239.8107AID1347411
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, BROMODOMAIN-CONTAINING PROTEIN 2Homo sapiens (human)IC50 (µMol)0.50000.50000.50000.5000AID977608
Chain A, BROMODOMAIN-CONTAINING PROTEIN 2Homo sapiens (human)IC50 (µMol)0.50000.50000.50000.5000AID977608
Bromodomain-containing protein 4Homo sapiens (human)IC50 (µMol)0.30540.00040.40329.0500AID1191950; AID1196538; AID1196539; AID1229997; AID1229998; AID1289237; AID1371238; AID1371243; AID1462229; AID1496412; AID1666115; AID1666119; AID1711598; AID1721373; AID1721374; AID1784030; AID1784031; AID1784038; AID1802212; AID705871; AID731806; AID772237; AID772239
Bromodomain-containing protein 4Homo sapiens (human)Ki0.10230.00530.05330.3850AID1229997; AID1229998; AID1371238; AID1371243; AID1535628; AID1535629
Cytochrome P450 3A4Homo sapiens (human)IC50 (µMol)9.70000.00011.753610.0000AID1784027; AID1784034; AID656144; AID705864
Cytochrome P450 2C9 Homo sapiens (human)IC50 (µMol)7.48750.00002.800510.0000AID1196537; AID1784033; AID656143; AID705866
Bromodomain-containing protein 2Homo sapiens (human)IC50 (µMol)0.31270.00090.53357.4000AID1196536; AID1666117; AID1666121; AID705873
Bromodomain-containing protein 2Homo sapiens (human)Ki0.02930.00050.04470.2200AID1229999; AID1230000
cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)IC50 (µMol)3.98110.00001.104010.0000AID705629
Bromodomain-containing protein 3Homo sapiens (human)IC50 (µMol)0.15310.00030.28713.9620AID1196537; AID1666116; AID1666120; AID705872
Bromodomain-containing protein 3Homo sapiens (human)Ki0.01470.00400.02230.0940AID1230001; AID1230002
Bromodomain testis-specific proteinHomo sapiens (human)IC50 (µMol)0.58010.00400.76925.0270AID1666118; AID1666131; AID1802212
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Bromodomain-containing Protein 4Homo sapiens (human)Kd0.10000.10000.10000.1000AID977611
Bromodomain-containing protein 4Homo sapiens (human)Kd0.13390.00100.36918.9300AID1230007; AID1230008
Bromodomain-containing protein 2Homo sapiens (human)Kd0.06250.00620.82325.8000AID1230003; AID1230004
Bromodomain-containing protein 3Homo sapiens (human)Kd0.03510.01170.67664.0650AID1230005; AID1230006
CREB-binding proteinHomo sapiens (human)Kd3.08403.08406.32809.6000AID1230009
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (116)

Processvia Protein(s)Taxonomy
regulation of transcription by RNA polymerase IIBromodomain-containing protein 4Homo sapiens (human)
positive regulation of G2/M transition of mitotic cell cycleBromodomain-containing protein 4Homo sapiens (human)
positive regulation of transcription elongation by RNA polymerase IIBromodomain-containing protein 4Homo sapiens (human)
chromatin organizationBromodomain-containing protein 4Homo sapiens (human)
DNA damage responseBromodomain-containing protein 4Homo sapiens (human)
positive regulation of transcription elongation by RNA polymerase IIBromodomain-containing protein 4Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionBromodomain-containing protein 4Homo sapiens (human)
positive regulation of DNA-templated transcriptionBromodomain-containing protein 4Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIBromodomain-containing protein 4Homo sapiens (human)
regulation of inflammatory responseBromodomain-containing protein 4Homo sapiens (human)
positive regulation of T-helper 17 cell lineage commitmentBromodomain-containing protein 4Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C9 Homo sapiens (human)
steroid metabolic processCytochrome P450 2C9 Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2C9 Homo sapiens (human)
estrogen metabolic processCytochrome P450 2C9 Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C9 Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
urea metabolic processCytochrome P450 2C9 Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 2C9 Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C9 Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
amide metabolic processCytochrome P450 2C9 Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
oxidative demethylationCytochrome P450 2C9 Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
neural tube closureBromodomain-containing protein 2Homo sapiens (human)
nucleosome assemblyBromodomain-containing protein 2Homo sapiens (human)
regulation of transcription by RNA polymerase IIBromodomain-containing protein 2Homo sapiens (human)
spermatogenesisBromodomain-containing protein 2Homo sapiens (human)
protein localization to chromatinBromodomain-containing protein 2Homo sapiens (human)
chromatin loopingBromodomain-containing protein 2Homo sapiens (human)
positive regulation of T-helper 17 cell lineage commitmentBromodomain-containing protein 2Homo sapiens (human)
neutrophil homeostasiscAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
cAMP catabolic processcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
neutrophil chemotaxiscAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
positive regulation of type II interferon productioncAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
positive regulation of interleukin-2 productioncAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
T cell receptor signaling pathwaycAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
leukocyte migrationcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
cellular response to lipopolysaccharidecAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
cellular response to xenobiotic stimuluscAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
cellular response to epinephrine stimuluscAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
negative regulation of adenylate cyclase-activating adrenergic receptor signaling pathwaycAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
regulation of cardiac muscle cell contractioncAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
negative regulation of relaxation of cardiac musclecAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
regulation of calcium ion transmembrane transport via high voltage-gated calcium channelcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
cAMP-mediated signalingcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
chromatin organizationBromodomain-containing protein 3Homo sapiens (human)
regulation of transcription by RNA polymerase IIBromodomain-containing protein 3Homo sapiens (human)
endodermal cell differentiationBromodomain-containing protein 3Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIBromodomain-containing protein 3Homo sapiens (human)
protein localization to chromatinBromodomain-containing protein 3Homo sapiens (human)
positive regulation of gene expressionBromodomain testis-specific proteinHomo sapiens (human)
chromatin remodelingBromodomain testis-specific proteinHomo sapiens (human)
regulation of DNA-templated transcriptionBromodomain testis-specific proteinHomo sapiens (human)
mRNA processingBromodomain testis-specific proteinHomo sapiens (human)
male meiotic nuclear divisionBromodomain testis-specific proteinHomo sapiens (human)
male meiosis IBromodomain testis-specific proteinHomo sapiens (human)
RNA splicingBromodomain testis-specific proteinHomo sapiens (human)
sperm DNA condensationBromodomain testis-specific proteinHomo sapiens (human)
regulation of RNA splicingBromodomain testis-specific proteinHomo sapiens (human)
positive regulation of DNA-templated transcriptionBromodomain testis-specific proteinHomo sapiens (human)
positive regulation of DNA-templated transcriptionATPase family AAA domain-containing protein 2Homo sapiens (human)
transcription initiation-coupled chromatin remodelingATPase family AAA domain-containing protein 2Homo sapiens (human)
nucleosome disassemblyATPase family AAA domain-containing protein 2Homo sapiens (human)
nucleosome assemblyATPase family AAA domain-containing protein 2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICREB-binding proteinHomo sapiens (human)
response to hypoxiaCREB-binding proteinHomo sapiens (human)
stimulatory C-type lectin receptor signaling pathwayCREB-binding proteinHomo sapiens (human)
chromatin remodelingCREB-binding proteinHomo sapiens (human)
regulation of DNA-templated transcriptionCREB-binding proteinHomo sapiens (human)
protein acetylationCREB-binding proteinHomo sapiens (human)
signal transductionCREB-binding proteinHomo sapiens (human)
canonical NF-kappaB signal transductionCREB-binding proteinHomo sapiens (human)
regulation of smoothened signaling pathwayCREB-binding proteinHomo sapiens (human)
negative regulation of transcription by RNA polymerase ICREB-binding proteinHomo sapiens (human)
N-terminal peptidyl-lysine acetylationCREB-binding proteinHomo sapiens (human)
positive regulation of transforming growth factor beta receptor signaling pathwayCREB-binding proteinHomo sapiens (human)
protein destabilizationCREB-binding proteinHomo sapiens (human)
cellular response to nutrient levelsCREB-binding proteinHomo sapiens (human)
cellular response to UVCREB-binding proteinHomo sapiens (human)
homeostatic processCREB-binding proteinHomo sapiens (human)
embryonic digit morphogenesisCREB-binding proteinHomo sapiens (human)
positive regulation of DNA-templated transcriptionCREB-binding proteinHomo sapiens (human)
positive regulation of transcription by RNA polymerase IICREB-binding proteinHomo sapiens (human)
rhythmic processCREB-binding proteinHomo sapiens (human)
protein-containing complex assemblyCREB-binding proteinHomo sapiens (human)
regulation of cellular response to heatCREB-binding proteinHomo sapiens (human)
positive regulation of protein localization to nucleusCREB-binding proteinHomo sapiens (human)
positive regulation of double-strand break repair via homologous recombinationCREB-binding proteinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (73)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingBromodomain-containing protein 4Homo sapiens (human)
p53 bindingBromodomain-containing protein 4Homo sapiens (human)
chromatin bindingBromodomain-containing protein 4Homo sapiens (human)
transcription coregulator activityBromodomain-containing protein 4Homo sapiens (human)
transcription coactivator activityBromodomain-containing protein 4Homo sapiens (human)
protein bindingBromodomain-containing protein 4Homo sapiens (human)
RNA polymerase II CTD heptapeptide repeat kinase activityBromodomain-containing protein 4Homo sapiens (human)
enzyme bindingBromodomain-containing protein 4Homo sapiens (human)
lysine-acetylated histone bindingBromodomain-containing protein 4Homo sapiens (human)
RNA polymerase II C-terminal domain bindingBromodomain-containing protein 4Homo sapiens (human)
P-TEFb complex bindingBromodomain-containing protein 4Homo sapiens (human)
histone reader activityBromodomain-containing protein 4Homo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
iron ion bindingCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
caffeine oxidase activityCytochrome P450 2C9 Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
aromatase activityCytochrome P450 2C9 Homo sapiens (human)
heme bindingCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C9 Homo sapiens (human)
chromatin bindingBromodomain-containing protein 2Homo sapiens (human)
protein serine/threonine kinase activityBromodomain-containing protein 2Homo sapiens (human)
protein bindingBromodomain-containing protein 2Homo sapiens (human)
lysine-acetylated histone bindingBromodomain-containing protein 2Homo sapiens (human)
acetylation-dependent protein bindingBromodomain-containing protein 2Homo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
calcium channel regulator activitycAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
protein bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
cAMP bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
gamma-tubulin bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
transmembrane transporter bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
metal ion bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
chromatin bindingBromodomain-containing protein 3Homo sapiens (human)
protein bindingBromodomain-containing protein 3Homo sapiens (human)
lysine-acetylated histone bindingBromodomain-containing protein 3Homo sapiens (human)
lncRNA bindingBromodomain-containing protein 3Homo sapiens (human)
molecular condensate scaffold activityBromodomain-containing protein 3Homo sapiens (human)
transcription coactivator activityBromodomain testis-specific proteinHomo sapiens (human)
histone bindingBromodomain testis-specific proteinHomo sapiens (human)
lysine-acetylated histone bindingBromodomain testis-specific proteinHomo sapiens (human)
histone reader activityBromodomain testis-specific proteinHomo sapiens (human)
protein bindingATPase family AAA domain-containing protein 2Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 2Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 2Homo sapiens (human)
histone bindingATPase family AAA domain-containing protein 2Homo sapiens (human)
chromatin bindingATPase family AAA domain-containing protein 2Homo sapiens (human)
transcription coactivator bindingCREB-binding proteinHomo sapiens (human)
p53 bindingCREB-binding proteinHomo sapiens (human)
chromatin bindingCREB-binding proteinHomo sapiens (human)
damaged DNA bindingCREB-binding proteinHomo sapiens (human)
transcription coactivator activityCREB-binding proteinHomo sapiens (human)
transcription corepressor activityCREB-binding proteinHomo sapiens (human)
histone acetyltransferase activityCREB-binding proteinHomo sapiens (human)
protein bindingCREB-binding proteinHomo sapiens (human)
zinc ion bindingCREB-binding proteinHomo sapiens (human)
acetyltransferase activityCREB-binding proteinHomo sapiens (human)
peptide N-acetyltransferase activityCREB-binding proteinHomo sapiens (human)
MRF bindingCREB-binding proteinHomo sapiens (human)
histone H3K18 acetyltransferase activityCREB-binding proteinHomo sapiens (human)
histone H3K27 acetyltransferase activityCREB-binding proteinHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCREB-binding proteinHomo sapiens (human)
peptide-lysine-N-acetyltransferase activityCREB-binding proteinHomo sapiens (human)
peptide lactyltransferase activityCREB-binding proteinHomo sapiens (human)
DNA-binding transcription factor bindingCREB-binding proteinHomo sapiens (human)
chromatin DNA bindingCREB-binding proteinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (25)

Processvia Protein(s)Taxonomy
condensed nuclear chromosomeBromodomain-containing protein 4Homo sapiens (human)
nucleusBromodomain-containing protein 4Homo sapiens (human)
nucleoplasmBromodomain-containing protein 4Homo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C9 Homo sapiens (human)
plasma membraneCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
cytoplasmCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
chromatinBromodomain-containing protein 2Homo sapiens (human)
nucleusBromodomain-containing protein 2Homo sapiens (human)
nucleoplasmBromodomain-containing protein 2Homo sapiens (human)
cytoplasmBromodomain-containing protein 2Homo sapiens (human)
nuclear speckBromodomain-containing protein 2Homo sapiens (human)
centrosomecAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
cytosolcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
synaptic vesiclecAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
postsynaptic densitycAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
Z disccAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
dendritic spinecAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
excitatory synapsecAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
gamma-tubulin complexcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
voltage-gated calcium channel complexcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
nucleuscAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
perinuclear region of cytoplasmcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
cytosolcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
nucleusBromodomain-containing protein 3Homo sapiens (human)
chromatinBromodomain-containing protein 3Homo sapiens (human)
nucleusBromodomain testis-specific proteinHomo sapiens (human)
nucleusATPase family AAA domain-containing protein 2Homo sapiens (human)
nucleoplasmATPase family AAA domain-containing protein 2Homo sapiens (human)
extracellular exosomeATPase family AAA domain-containing protein 2Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 2Homo sapiens (human)
cytoplasmCREB-binding proteinHomo sapiens (human)
nucleusCREB-binding proteinHomo sapiens (human)
nucleoplasmCREB-binding proteinHomo sapiens (human)
cytoplasmCREB-binding proteinHomo sapiens (human)
cytosolCREB-binding proteinHomo sapiens (human)
nuclear bodyCREB-binding proteinHomo sapiens (human)
chromatinCREB-binding proteinHomo sapiens (human)
histone acetyltransferase complexCREB-binding proteinHomo sapiens (human)
transcription regulator complexCREB-binding proteinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (243)

Assay IDTitleYearJournalArticle
AID1347414qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Secondary screen by immunofluorescence2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1645848NCATS Kinetic Aqueous Solubility Profiling2019Bioorganic & medicinal chemistry, 07-15, Volume: 27, Issue:14
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347157Confirmatory screen GU Rhodamine qHTS for Zika virus inhibitors qHTS2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347161Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347412qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347169Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1230018Cytotoxicity against human MV4-11 cells harboring MLL1 fusion gene assessed as growth inhibition after 4 days by CellTiter-Glo luminescent assay2015Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12
Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors.
AID1230004Binding affinity to biotinylated BRD2 BD2 (349 to 460 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells by bio-layer interferometry method2015Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12
Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors.
AID1666135Selectivity index, difference between pIC50 for N-terminal His6-tagged human BRDT BD1 (1 to 397 residues)/ BD2 Y309A mutant expressed in Escherichia coli to pIC50 for N-terminal His6-tagged human BRDT BD2 (1 to 397 residues)/BD1 Y66A mutant expressed in E2020Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17
Structure-Based Design of a Bromodomain and Extraterminal Domain (BET) Inhibitor Selective for the N-Terminal Bromodomains That Retains an Anti-inflammatory and Antiproliferative Phenotype.
AID1371319Toxicity in SCID mouse implanted with human MV-411 cells assessed as weight loss at 50 mg/kg, po qd measured 2 to 3 times weekly during treatment and weekly post dose2017Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
Structure-Based Discovery of 4-(6-Methoxy-2-methyl-4-(quinolin-4-yl)-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole (CD161) as a Potent and Orally Bioavailable BET Bromodomain Inhibitor.
AID1196557Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac substrate preincubated for 5 mins before NADPH addition and measured after 20 mins post NADPH addition2015Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3
Fragment-based drug discovery of 2-thiazolidinones as BRD4 inhibitors: 2. Structure-based optimization.
AID705632Mutagenicity against Salmonella typhimurium TA98 by AMES test in absence of S9 fraction2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).
AID656152Antiinflammatory activity in LPS-stimulated acute inflammation BALB/c mouse model assessed as inhibition of plasma MCP-1 level at 10 mg/kg, po administered 2 hrs before LPS challenge2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.
AID656151Antiinflammatory activity in LPS-stimulated acute inflammation BALB/c mouse model assessed as inhibition of plasma IL-6 level at 10 mg/kg, po administered 2 hrs before LPS challenge2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.
AID656150Antiinflammatory activity in LPS-stimulated acute inflammation BALB/c mouse model assessed as inhibition of plasma PAI-1 level at 10 mg/kg, po administered 2 hrs before LPS challenge2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.
AID705864Inhibition of CYP3A4 using diethoxyfluoresin as substrate2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).
AID772239Inhibition of His-FLAG-tagged BRD4 binding domain1 (unknown origin) binding to H4-TetraAc-biotin peptide after 20 mins by AlphaLISA2013ACS medicinal chemistry letters, Sep-12, Volume: 4, Issue:9
Discovery, Design, and Optimization of Isoxazole Azepine BET Inhibitors.
AID1666121Displacement of Alexa Fluor 647 labelled I-BET762 from N-terminal His6-tagged human BRD2 BD1 (1 to 473 residues)/BD2 Y386A mutant expressed in Escherichia coli after 1 hr by TR-FRET assay2020Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17
Structure-Based Design of a Bromodomain and Extraterminal Domain (BET) Inhibitor Selective for the N-Terminal Bromodomains That Retains an Anti-inflammatory and Antiproliferative Phenotype.
AID1196558Inhibition of CYP1A2 in human liver microsomes at 10 uM using phenacetin substrate preincubated for 5 mins before NADPH addition and measured after 20 mins post NADPH addition2015Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3
Fragment-based drug discovery of 2-thiazolidinones as BRD4 inhibitors: 2. Structure-based optimization.
AID1230001Displacement of FAM-labeled ZBA248 from BRD3 BD1 (24 to 144 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells after 30 mins by fluorescence polarization assay2015Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12
Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors.
AID1666113Growth inhibition of human MV4-11 cells incubated for 72 hrs by Cell-titre glo assay2020Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17
Structure-Based Design of a Bromodomain and Extraterminal Domain (BET) Inhibitor Selective for the N-Terminal Bromodomains That Retains an Anti-inflammatory and Antiproliferative Phenotype.
AID1784027Inhibition of recombinant human CYP3A4 expressed in Escherichia coli using VG as probe substrate incubated for 15 to 60 mins by fluorometric assay2021Journal of medicinal chemistry, 08-26, Volume: 64, Issue:16
Discovery of a Novel Bromodomain and Extra Terminal Domain (BET) Protein Inhibitor, I-BET282E, Suitable for Clinical Progression.
AID1371238Inhibition of FAM-labeled ZBA248 binding to recombinant human N-terminal His6-tagged BRD4 bromodomain 2 (333 to 460 residues) expressed in Rosetta2 DE3 cells after 30 mins by Flourescence polarization assay2017Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
Structure-Based Discovery of 4-(6-Methoxy-2-methyl-4-(quinolin-4-yl)-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole (CD161) as a Potent and Orally Bioavailable BET Bromodomain Inhibitor.
AID1196553Stability in human liver microsomes assessed as clearance at 1 uM pre-incubated for 5 mins followed by NADPH addition and measured after 5 to 30 mins post NADPH addition by LC/MS/MS method2015Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3
Fragment-based drug discovery of 2-thiazolidinones as BRD4 inhibitors: 2. Structure-based optimization.
AID1721373Displacement of Alexa Fluor 647 labelled ligand from His6-thr-tagged BRD4 BD1 (1 to 477 residues)/BD2 Y390A mutant (unknown origin) after 30 mins by TR-FRET assay2020Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17
GSK789: A Selective Inhibitor of the First Bromodomains (BD1) of the Bromo and Extra Terminal Domain (BET) Proteins.
AID1196564Time dependent inhibition of CYP2C19 in human liver microsomes at 10 uM using mephenytoin substrate preincubated for 5 mins before NADPH addition and measured after 20 mins post NADPH addition2015Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3
Fragment-based drug discovery of 2-thiazolidinones as BRD4 inhibitors: 2. Structure-based optimization.
AID1535619Binding affinity to recombinant human N-terminal TEV-cleavable hexa-histidine tagged BRD2 bromodomain1 assessed as change in melting temperature at 30 uM measured after 30 mins by SYPRO orange dye based differential scanning fluorimetry2019Bioorganic & medicinal chemistry, 02-01, Volume: 27, Issue:3
Structure-guided discovery of a novel, potent, and orally bioavailable 3,5-dimethylisoxazole aryl-benzimidazole BET bromodomain inhibitor.
AID705624Blood clearance in mini pig2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).
AID1229999Displacement of FAM-labeled ZBA248 from BRD2 BD1 (72 to 205 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells after 30 mins by fluorescence polarization assay2015Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12
Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors.
AID1666119Displacement of Alexa Fluor 647 labelled I-BET762 from N-terminal His6-tagged human BRD4 BD1 (1 to 477 residues)/BD2 Y390A mutant expressed in Escherichia coli after 1 hr by TR-FRET assay2020Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17
Structure-Based Design of a Bromodomain and Extraterminal Domain (BET) Inhibitor Selective for the N-Terminal Bromodomains That Retains an Anti-inflammatory and Antiproliferative Phenotype.
AID1191950Inhibition of BRD4 bromodomain-1 (unknown origin) by europium based LANCE TR-FRET assay2015Bioorganic & medicinal chemistry, Mar-01, Volume: 23, Issue:5
Discovery and structure-activity relationship studies of N6-benzoyladenine derivatives as novel BRD4 inhibitors.
AID705627Oral bioavailability in dog2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).
AID1196540Growth inhibition of human HT-29 cells after 72 hrs by SRB assay2015Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3
Fragment-based drug discovery of 2-thiazolidinones as BRD4 inhibitors: 2. Structure-based optimization.
AID1230002Displacement of FAM-labeled ZBA248 from BRD3 BD2 (306 to 417 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells after 30 mins by fluorescence polarization assay2015Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12
Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors.
AID705619Half life in rat2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).
AID705654Fraction unbound in human blood after 4 hrs by rapid equilibrium dialysis2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).
AID1666134Selectivity index, difference between pIC50 for N-terminal His6-tagged human BRD4 BD1 (1 to 477 residues)/BD2 Y390A mutant expressed in Escherichia coli to pIC50 for N-terminal His6-tagged human BRD4 BD2 (1 to 477 residues)/BD1 Y97A mutant expressed in Es2020Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17
Structure-Based Design of a Bromodomain and Extraterminal Domain (BET) Inhibitor Selective for the N-Terminal Bromodomains That Retains an Anti-inflammatory and Antiproliferative Phenotype.
AID1721367Inhibition of LPS-induced IL6 production in human whole blood preincubated for 30 mins followed by LPS addition and measured after overnight incubation by mesoscale assay2020Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17
GSK789: A Selective Inhibitor of the First Bromodomains (BD1) of the Bromo and Extra Terminal Domain (BET) Proteins.
AID1349421Inhibition of BRD4 in human MV4-11 cells assessed as downregulation of BCL2 RNA expression by RNA-seq analysis2017ACS medicinal chemistry letters, Dec-14, Volume: 8, Issue:12
Design, Synthesis, and Biological Activity of 1,2,3-Triazolobenzodiazepine BET Bromodomain Inhibitors.
AID1784037Metabolic stability in human hepatocytes assessed as intrinsic clearance per g liver tissue at 0.5 uM measured upto 120 mins by LC-MS/MS analysis2021Journal of medicinal chemistry, 08-26, Volume: 64, Issue:16
Discovery of a Novel Bromodomain and Extra Terminal Domain (BET) Protein Inhibitor, I-BET282E, Suitable for Clinical Progression.
AID705630Oral bioavailability in rat2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).
AID1535621Binding affinity to recombinant human N-terminal TEV-cleavable hexa-histidine tagged BRD3 bromodomain1 assessed as change in melting temperature at 30 uM measured after 30 mins by SYPRO orange dye based differential scanning fluorimetry2019Bioorganic & medicinal chemistry, 02-01, Volume: 27, Issue:3
Structure-guided discovery of a novel, potent, and orally bioavailable 3,5-dimethylisoxazole aryl-benzimidazole BET bromodomain inhibitor.
AID705870Inhibition of BET in human HepG2 cells assessed as upregulation of ApoA1 after 18 hrs by luciferase reporter gene assay2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).
AID1196563Time dependent inhibition of CYP1A2 in human liver microsomes at 10 uM using phenacetin substrate preincubated for 5 mins before NADPH addition and measured after 20 mins post NADPH addition2015Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3
Fragment-based drug discovery of 2-thiazolidinones as BRD4 inhibitors: 2. Structure-based optimization.
AID705611Antiinflammatory activity in mouse endotoxaemia model assessed as protection against LPS-induced mortality at 10 mg/kg, iv administered 90 mins post LPS challenge measured up to 4 days2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).
AID705622Blood clearance in mouse2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).
AID1535628Inhibition of Cy5-linked JQ1 probe binding to recombinant human N-terminal TEV-cleavable hexa-histidine tagged BRD4 bromodomain2 after 60 mins by HTRF assay2019Bioorganic & medicinal chemistry, 02-01, Volume: 27, Issue:3
Structure-guided discovery of a novel, potent, and orally bioavailable 3,5-dimethylisoxazole aryl-benzimidazole BET bromodomain inhibitor.
AID705649Time dependent inhibition of CYP3A4 using diethoxyfluoresin as substrate2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).
AID656154Dose normalized AUC (0 to infinity ) in CD rat2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.
AID1230003Binding affinity to biotinylated BRD2 BD1 (72 to 205 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells by bio-layer interferometry method2015Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12
Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors.
AID1196560Time dependent inhibition of CYP3A4 in human liver microsomes at 10 uM using midazolam substrate preincubated for 5 mins before NADPH addition and measured after 20 mins post NADPH addition2015Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3
Fragment-based drug discovery of 2-thiazolidinones as BRD4 inhibitors: 2. Structure-based optimization.
AID705642Intrinsic clearance in dog hepatocytes assessed per mg of protein at 0.5 uM after 30 mins2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).
AID656144Inhibition of CYP3A42012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.
AID1196536Inhibition of BRD2 (unknown origin) by fluorescence anisotrophy2015Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3
Fragment-based drug discovery of 2-thiazolidinones as BRD4 inhibitors: 2. Structure-based optimization.
AID1821859Anti-inflammatory activity in human liver sinusoidal endothelial cells assessed as residual CXCL1 mRNA levels at 1.3 uM incubated for 2 hrs followed by LPS induction for 4 hrs by SYBR green staining based qRT-PCR analysis2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
A Structure-based Design Approach for Generating High Affinity BRD4 D1-Selective Chemical Probes.
AID1784032Solubility of the compound in FaSSIF at pH 6.5 measured after 30 mins by HPLC analysis2021Journal of medicinal chemistry, 08-26, Volume: 64, Issue:16
Discovery of a Novel Bromodomain and Extra Terminal Domain (BET) Protein Inhibitor, I-BET282E, Suitable for Clinical Progression.
AID1666132Selectivity index, difference between pIC50 for N-terminal His6-tagged human BRD2 BD1 (1 to 473 residues)/ BD2 Y386A mutant expressed in Escherichia coli to pIC50 for N-terminal His6-tagged human BRD2 BD2 (1 to 473 residues)/BD1 Y113A mutant expressed in 2020Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17
Structure-Based Design of a Bromodomain and Extraterminal Domain (BET) Inhibitor Selective for the N-Terminal Bromodomains That Retains an Anti-inflammatory and Antiproliferative Phenotype.
AID1196556Inhibition of CYP2D6 in human liver microsomes at 10 uM using dextromethorphan substrate preincubated for 5 mins before NADPH addition and measured after 20 mins post NADPH addition2015Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3
Fragment-based drug discovery of 2-thiazolidinones as BRD4 inhibitors: 2. Structure-based optimization.
AID1535622Binding affinity to recombinant human N-terminal TEV-cleavable hexa-histidine tagged BRD3 bromodomain2 assessed as change in melting temperature at 30 uM measured after 30 mins by SYPRO orange dye based differential scanning fluorimetry2019Bioorganic & medicinal chemistry, 02-01, Volume: 27, Issue:3
Structure-guided discovery of a novel, potent, and orally bioavailable 3,5-dimethylisoxazole aryl-benzimidazole BET bromodomain inhibitor.
AID705633Mutagenicity against Salmonella typhimurium TA1535 by AMES test in absence of S9 fraction2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).
AID1229997Displacement of FAM-labeled ZBA248 from BRD4 BD1 (44 to 168 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells after 30 mins by fluorescence polarization assay2015Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12
Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors.
AID705867Antiinflammatory activity in human PBMC assessed as inhibition of LPS-induced IL6 production2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).
AID1196549Inhibition of BRD4 in human HT-29 cells assessed as reduction in c-Myc protein expression at 0.3125 uM to 5 uM uM after 24 hrs by Western blotting method2015Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3
Fragment-based drug discovery of 2-thiazolidinones as BRD4 inhibitors: 2. Structure-based optimization.
AID705615Antiinflammatory activity in mouse endotoxaemia model assessed as inhibition of LPS-induced IL6 production at 10 mg/kg, iv administered 1 hr prior to LPS challenge measured after 90 mins by ELISA relative to vehicle-treated control2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).
AID1666118Displacement of Alexa Fluor 647 labelled I-BET762 from N-terminal His6-tagged human BRDT BD1 (1 to 397 residues)/BD2 Y309A mutant expressed in Escherichia coli after 1 hr by TR-FRET assay2020Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17
Structure-Based Design of a Bromodomain and Extraterminal Domain (BET) Inhibitor Selective for the N-Terminal Bromodomains That Retains an Anti-inflammatory and Antiproliferative Phenotype.
AID705617Half life in mini pig2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).
AID1196561Time dependent inhibition of CYP2D6 in human liver microsomes at 10 uM using dextromethorphan substrate preincubated for 5 mins before NADPH addition and measured after 20 mins post NADPH addition2015Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3
Fragment-based drug discovery of 2-thiazolidinones as BRD4 inhibitors: 2. Structure-based optimization.
AID1416027Induction of apoptosis in human MV4-11 cells assessed as late apoptotic cells after 72 hrs by annexin-V-FITC/propidium iodide staining-based flow cytometric method (Rvb = 2.14%)2017MedChemComm, Jun-01, Volume: 8, Issue:6
Discovery of novel trimethoxy-ring BRD4 bromodomain inhibitors: AlphaScreen assay, crystallography and cell-based assay.
AID705623Volume of distribution in rat2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).
AID705625Blood clearance in dog2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).
AID705653Fraction unbound in dog blood after 4 hrs by rapid equilibrium dialysis2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).
AID656148Inhibition of LPS-stimulated TNFalpha production in human PBMC2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.
AID705640Mutagenicity against Salmonella typhimurium TA1537 by AMES test in presence of S9 fraction2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).
AID1196538Inhibition of BRD4 (unknown origin) by fluorescence anisotrophy2015Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3
Fragment-based drug discovery of 2-thiazolidinones as BRD4 inhibitors: 2. Structure-based optimization.
AID731806Binding affinity to human BRD4 1/2 bromodomain by fluorescence anisotropic assay2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
Optimization of 3,5-dimethylisoxazole derivatives as potent bromodomain ligands.
AID656143Inhibition of CYP2C92012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.
AID705643Intrinsic clearance in mini pig hepatocytes assessed per mg of protein at 0.5 uM after 30 mins2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).
AID1711598Inhibition of His/FLAG-tagged BRD4 BD1 (unknown origin) using histone H4-TetraAcetylated-biotin peptide as substrate incubated for 20 mins by AlphaLISA assay2016ACS medicinal chemistry letters, Feb-11, Volume: 7, Issue:2
Discovery of Benzotriazolo[4,3-d][1,4]diazepines as Orally Active Inhibitors of BET Bromodomains.
AID692861Binding affinity to BET2012ACS medicinal chemistry letters, Sep-13, Volume: 3, Issue:9
Bromodomains: are readers right for epigenetic therapy?
AID705618Volume of distribution in mouse2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).
AID705616Half life in dog2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).
AID705645Intrinsic clearance in mini pig liver microsomes assessed per mg of protein at 0.5 uM after 30 mins2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).
AID1821858Anti-inflammatory activity in human liver sinusoidal endothelial cells assessed as residual CCL2 mRNA levels at 1.3 uM incubated for 2 hrs followed by LPS induction for 4 hrs by SYBR green staining based qRT-PCR analysis2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
A Structure-based Design Approach for Generating High Affinity BRD4 D1-Selective Chemical Probes.
AID1721374Displacement of Alexa Fluor 647 labelled ligand from His6-tagged BRD4 BD2 (1 to 477 residues)/BD1 Y97A mutant (unknown origin) after 30 mins by TR-FRET assay2020Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17
GSK789: A Selective Inhibitor of the First Bromodomains (BD1) of the Bromo and Extra Terminal Domain (BET) Proteins.
AID1196539Inhibition of BRD4(1) (unknown origin) incubated for 4 hrs by (+)-JQ1 fluorescent ligand based fluorescence anisotrophy2015Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3
Fragment-based drug discovery of 2-thiazolidinones as BRD4 inhibitors: 2. Structure-based optimization.
AID705628Oral bioavailability in mini pig2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).
AID705639Mutagenicity against Escherichia coli WP2uvrA by AMES test in presence of S9 fraction2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).
AID705629Inhibition of PDE4B2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).
AID705636Mutagenicity against Salmonella typhimurium TA100 by AMES test in presence of S9 fraction2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).
AID705621Volume of distribution in mini pig2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).
AID705655Fraction unbound in mouse blood after 4 hrs by rapid equilibrium dialysis2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).
AID1784031Inhibition of BRD4 in human whole blood assessed as reduction in LPS-induced IL-6 secretion preincubated for 30 mins followed by LPS stimulation and measured after 24 hrs by MSD assay2021Journal of medicinal chemistry, 08-26, Volume: 64, Issue:16
Discovery of a Novel Bromodomain and Extra Terminal Domain (BET) Protein Inhibitor, I-BET282E, Suitable for Clinical Progression.
AID1585512Inhibition of PCSK9 mRNA expression in mouse primary hepatocytes at 2.5 uM after 24 hrs relative to control2019European journal of medicinal chemistry, Jan-15, Volume: 162Small molecules as inhibitors of PCSK9: Current status and future challenges.
AID1230006Binding affinity to biotinylated BRD3 BD2 (306 to 417 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells by bio-layer interferometry method2015Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12
Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors.
AID705865Cytotoxicity against human PBMC assessed as decrease in ATP level2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).
AID1496412Inhibition of BRD4 (unknown origin) by fluorescence polarization assay2018Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11
BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
AID1462229Inhibition of BRD4 (unknown origin) by fluorescence anisotropy ligand displacement assay2017Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17
Structure-based design, synthesis and in vitro antiproliferative effects studies of novel dual BRD4/HDAC inhibitors.
AID1666115Displacement of Alexa Fluor 647 labelled I-BET762 from N-terminal His6-tagged human BRD4 BD2 (1 to 477 residues)/BD1 Y97A mutant expressed in Escherichia coli after 1 hr by TR-FRET assay2020Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17
Structure-Based Design of a Bromodomain and Extraterminal Domain (BET) Inhibitor Selective for the N-Terminal Bromodomains That Retains an Anti-inflammatory and Antiproliferative Phenotype.
AID705637Mutagenicity against Salmonella typhimurium TA98 by AMES test in presence of S9 fraction2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).
AID1721413Antiproliferative activity against human THP-1 cells after 72 hrs by cell titer glo assay2020Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17
GSK789: A Selective Inhibitor of the First Bromodomains (BD1) of the Bromo and Extra Terminal Domain (BET) Proteins.
AID1535620Binding affinity to recombinant human N-terminal TEV-cleavable hexa-histidine tagged BRD2 bromodomain2 assessed as change in melting temperature at 30 uM measured after 30 mins by SYPRO orange dye based differential scanning fluorimetry2019Bioorganic & medicinal chemistry, 02-01, Volume: 27, Issue:3
Structure-guided discovery of a novel, potent, and orally bioavailable 3,5-dimethylisoxazole aryl-benzimidazole BET bromodomain inhibitor.
AID1196537Inhibition of BRD3 (unknown origin) by fluorescence anisotrophy2015Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3
Fragment-based drug discovery of 2-thiazolidinones as BRD4 inhibitors: 2. Structure-based optimization.
AID1230007Binding affinity to biotinylated BRD4 BD1 (44 to 168 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells by bio-layer interferometry method2015Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12
Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors.
AID656146Bioactivation in rat hepatocytes assessed as compound epoxidation2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.
AID1196542Growth inhibition of human MM1S cells after 72 hrs by SRB assay2015Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3
Fragment-based drug discovery of 2-thiazolidinones as BRD4 inhibitors: 2. Structure-based optimization.
AID705647Intrinsic clearance in dog liver microsomes assessed per mg of protein at 0.5 uM after 30 mins2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).
AID656149Inhibition of LPS-stimulated IL-6 production in human PBMC2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.
AID1196559Inhibition of CYP2C19 in human liver microsomes at 10 uM using mephenytoin substrate preincubated for 5 mins before NADPH addition and measured after 20 mins post NADPH addition2015Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3
Fragment-based drug discovery of 2-thiazolidinones as BRD4 inhibitors: 2. Structure-based optimization.
AID1416020Cell cycle arrest in human MV4-11 cells assessed as accumulation at S phase after 24 hrs by propidium iodide staining-based flow cytometric method (Rvb = 33.52%)2017MedChemComm, Jun-01, Volume: 8, Issue:6
Discovery of novel trimethoxy-ring BRD4 bromodomain inhibitors: AlphaScreen assay, crystallography and cell-based assay.
AID1784035Metabolic stability in rat hepatocytes assessed as intrinsic clearance per g liver tissue at 0.5 uM measured upto 120 mins by LC-MS/MS analysis2021Journal of medicinal chemistry, 08-26, Volume: 64, Issue:16
Discovery of a Novel Bromodomain and Extra Terminal Domain (BET) Protein Inhibitor, I-BET282E, Suitable for Clinical Progression.
AID1371320Toxicity in SCID mouse implanted with human MV4-11 cells at 50 mg/kg, po qd measured 2 to 3 times weekly during treatment and once weekly post dose2017Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
Structure-Based Discovery of 4-(6-Methoxy-2-methyl-4-(quinolin-4-yl)-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole (CD161) as a Potent and Orally Bioavailable BET Bromodomain Inhibitor.
AID705858Fraction unbound in rat blood after 4 hrs by rapid equilibrium dialysis2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).
AID1230008Binding affinity to biotinylated BRD4 BD2 (333 to 460 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells by bio-layer interferometry method2015Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12
Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors.
AID705610Time dependent inhibition of CYP2D62012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).
AID1666110Antiinflammatory activity in human PBMC assessed as reduction in LPS-induced IL-6 production incubated for 18 to 24 hrs by mesoscale assay2020Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17
Structure-Based Design of a Bromodomain and Extraterminal Domain (BET) Inhibitor Selective for the N-Terminal Bromodomains That Retains an Anti-inflammatory and Antiproliferative Phenotype.
AID1535625Binding affinity to recombinant human N-terminal TEV-cleavable hexa-histidine tagged CREBBP assessed as change in melting temperature at 30 uM measured after 30 mins by SYPRO orange dye based differential scanning fluorimetry2019Bioorganic & medicinal chemistry, 02-01, Volume: 27, Issue:3
Structure-guided discovery of a novel, potent, and orally bioavailable 3,5-dimethylisoxazole aryl-benzimidazole BET bromodomain inhibitor.
AID705860Antiinflammatory activity in human whole blood assessed as inhibition of LPS-induced IL12p70 production2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).
AID705613Antiinflammatory activity in mouse endotoxaemia model assessed as inhibition of LPS-induced TNFalpha production at 0.1 to 30 mg/kg, iv administered 1 hr prior to LPS-challenge measured after 90 mins by ELISA relative to vehicle-treated control2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).
AID706719Half life in mouse2012Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
Progress in the development and application of small molecule inhibitors of bromodomain-acetyl-lysine interactions.
AID1666116Displacement of Alexa Fluor 647 labelled I-BET762 from N-terminal His6-tagged human BRD3 BD2 (1 to 435 residues)/BD1 Y73A mutant expressed in Escherichia coli after 1 hr by TR-FRET assay2020Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17
Structure-Based Design of a Bromodomain and Extraterminal Domain (BET) Inhibitor Selective for the N-Terminal Bromodomains That Retains an Anti-inflammatory and Antiproliferative Phenotype.
AID705641Intrinsic clearance in human hepatocytes assessed per mg of protein at 0.5 uM after 30 mins2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).
AID1371243Inhibition of FAM-labeled ZBA248 binding to recombinant human N-terminal His6-tagged BRD4 bromodomain 1 (44 to 168 residues) expressed in Rosetta2 DE3 cells after 30 mins by Flourescence polarization assay2017Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
Structure-Based Discovery of 4-(6-Methoxy-2-methyl-4-(quinolin-4-yl)-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole (CD161) as a Potent and Orally Bioavailable BET Bromodomain Inhibitor.
AID656147Mutagenic activity in Salmonella typhimurium by Ames assay2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.
AID1371237Growth inhibition of human MV4-11 cells after 4 days by WST-8 assay2017Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
Structure-Based Discovery of 4-(6-Methoxy-2-methyl-4-(quinolin-4-yl)-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole (CD161) as a Potent and Orally Bioavailable BET Bromodomain Inhibitor.
AID1229998Displacement of FAM-labeled ZBA248 from BRD4 BD2 (333 to 460 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells after 30 mins by fluorescence polarization assay2015Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12
Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors.
AID1289237Inhibition of BRD4 bromodomain 1 (unknown origin)2016Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
Disrupting Acetyl-Lysine Recognition: Progress in the Development of Bromodomain Inhibitors.
AID1230020Cytotoxicity against human K562 cells harboring BCR-ABL fusion gene assessed as growth inhibition after 4 days by CellTiter-Glo luminescent assay2015Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12
Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors.
AID1666111Antiinflammatory activity in human PBMC assessed as reduction in LPS-induced MCP1 production incubated for 18 to 24 hrs by mesoscale assay2020Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17
Structure-Based Design of a Bromodomain and Extraterminal Domain (BET) Inhibitor Selective for the N-Terminal Bromodomains That Retains an Anti-inflammatory and Antiproliferative Phenotype.
AID656155Clearance in iv dosed CD rat blood after 1 hr2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.
AID705871Binding affinity to BRD4 assessed as inhibition of Alexa Fluor 488 binding after 60 mins by fluorescence anisotropic analysis2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).
AID656153Antiinflammatory activity in LPS-stimulated acute inflammation BALB/c mouse model assessed as inhibition of plasma TNF-alpha level at 10 mg/kg, po administered 2 hrs before LPS challenge2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.
AID705626Blood clearance in rat2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).
AID1371302Antitumor activity against human MV4-11 cells xenografted in SCID mouse assessed as tumor growth inhibition at 50 mg/kg, po qd measured 2 to 3 times weekly during treatment and once weekly post dose2017Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
Structure-Based Discovery of 4-(6-Methoxy-2-methyl-4-(quinolin-4-yl)-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole (CD161) as a Potent and Orally Bioavailable BET Bromodomain Inhibitor.
AID705638Mutagenicity against Salmonella typhimurium TA1535 by AMES test in presence of S9 fraction2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).
AID1535626Binding affinity to recombinant human N-terminal TEV-cleavable hexa-histidine tagged SMARCA4 assessed as change in melting temperature at 30 uM measured after 30 mins by SYPRO orange dye based differential scanning fluorimetry2019Bioorganic & medicinal chemistry, 02-01, Volume: 27, Issue:3
Structure-guided discovery of a novel, potent, and orally bioavailable 3,5-dimethylisoxazole aryl-benzimidazole BET bromodomain inhibitor.
AID705873Binding affinity to human BRD2 assessed as inhibition of Alexa Fluor 488 binding after 60 mins by fluorescence anisotropic analysis2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).
AID705866Inhibition of CYP2C92012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).
AID1784033Inhibition of recombinant human CYP2C9 expressed in Escherichia coli using FCA as substrate incubated for 15 to 60 mins by fluorometric assay2021Journal of medicinal chemistry, 08-26, Volume: 64, Issue:16
Discovery of a Novel Bromodomain and Extra Terminal Domain (BET) Protein Inhibitor, I-BET282E, Suitable for Clinical Progression.
AID1416026Induction of apoptosis in human MV4-11 cells assessed as early apoptotic cells after 72 hrs by annexin-V-FITC/propidium iodide staining-based flow cytometric method (Rvb = 1.64%)2017MedChemComm, Jun-01, Volume: 8, Issue:6
Discovery of novel trimethoxy-ring BRD4 bromodomain inhibitors: AlphaScreen assay, crystallography and cell-based assay.
AID1230010Binding affinity to biotinylated ATAD2A (981 to 1108 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells by bio-layer interferometry method2015Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12
Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors.
AID1535629Inhibition of tetra-acetylated Histone H4 peptide binding to recombinant human N-terminal TEV-cleavable hexa-histidine tagged BRD4 bromodomain1 after 60 mins by ALPHA screen assay2019Bioorganic & medicinal chemistry, 02-01, Volume: 27, Issue:3
Structure-guided discovery of a novel, potent, and orally bioavailable 3,5-dimethylisoxazole aryl-benzimidazole BET bromodomain inhibitor.
AID1371236Growth inhibition of human MOLM13 cells after 4 days by WST-8 assay2017Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
Structure-Based Discovery of 4-(6-Methoxy-2-methyl-4-(quinolin-4-yl)-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole (CD161) as a Potent and Orally Bioavailable BET Bromodomain Inhibitor.
AID705861Antiinflammatory activity in human whole blood assessed as inhibition of LPS-induced IL10 production2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).
AID705863Antiinflammatory activity in human whole blood assessed as inhibition of LPS-induced TNFalpha production2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).
AID1721412Antiproliferative activity against human HL-60 cells after 72 hrs by cell titer glo assay2020Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17
GSK789: A Selective Inhibitor of the First Bromodomains (BD1) of the Bromo and Extra Terminal Domain (BET) Proteins.
AID706718AUC (infinity) in mouse2012Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
Progress in the development and application of small molecule inhibitors of bromodomain-acetyl-lysine interactions.
AID656145Bioactivation in human hepatocytes assessed as compound epoxidation2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.
AID1666112Antiinflammatory activity in human whole blood assessed as reduction in LPS-induced IL-6 production preincubated for 30 mins followed by LPS challenge and measured after overnight incubation by mesoscale assay2020Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17
Structure-Based Design of a Bromodomain and Extraterminal Domain (BET) Inhibitor Selective for the N-Terminal Bromodomains That Retains an Anti-inflammatory and Antiproliferative Phenotype.
AID705644Intrinsic clearance in rat hepatocytes assessed per mg of protein at 0.5 uM after 30 mins2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).
AID705862Antiinflammatory activity in human whole blood assessed as inhibition of LPS-induced IL8 production2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).
AID1821857Cytotoxicity against human liver sinusoidal endothelial cells assessed as viable cells incubated for 20 to 24 hrs by XTT assay2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
A Structure-based Design Approach for Generating High Affinity BRD4 D1-Selective Chemical Probes.
AID1784036Metabolic stability in dog hepatocytes assessed as intrinsic clearance per g liver tissue at 0.5 uM measured upto 120 mins by LC-MS/MS analysis2021Journal of medicinal chemistry, 08-26, Volume: 64, Issue:16
Discovery of a Novel Bromodomain and Extra Terminal Domain (BET) Protein Inhibitor, I-BET282E, Suitable for Clinical Progression.
AID1721379Inhibition of LPS-induced MCP1 production in human whole blood preincubated for 30 mins followed by LPS addition and measured after overnight incubation by mesoscale assay2020Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17
GSK789: A Selective Inhibitor of the First Bromodomains (BD1) of the Bromo and Extra Terminal Domain (BET) Proteins.
AID1666114Antiinflammatory activity in human whole blood assessed as reduction in LPS-induced MCP1 production preincubated for 30 mins followed by LPS challenge and measured after overnight incubation by mesoscale assay2020Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17
Structure-Based Design of a Bromodomain and Extraterminal Domain (BET) Inhibitor Selective for the N-Terminal Bromodomains That Retains an Anti-inflammatory and Antiproliferative Phenotype.
AID705651Time dependent inhibition of CYP2C92012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).
AID705648Intrinsic clearance in rat liver microsomes assessed per mg of protein at 0.5 uM after 30 mins2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).
AID1196554Inhibition of CYP3A4 in human liver microsomes at 10 uM using midazolam substrate preincubated for 5 mins before NADPH addition and measured after 20 mins post NADPH addition2015Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3
Fragment-based drug discovery of 2-thiazolidinones as BRD4 inhibitors: 2. Structure-based optimization.
AID1416029Induction of apoptosis in human MV4-11 cells assessed as viable cells after 72 hrs by annexin-V-FITC/propidium iodide staining-based flow cytometric method (Rvb = 96.2%)2017MedChemComm, Jun-01, Volume: 8, Issue:6
Discovery of novel trimethoxy-ring BRD4 bromodomain inhibitors: AlphaScreen assay, crystallography and cell-based assay.
AID1784030Inhibition of BRD4 in human PBMC assessed as reduction in LPS-induced IL-6 secretion incubated for 18 to 24 hrs by MSD assay2021Journal of medicinal chemistry, 08-26, Volume: 64, Issue:16
Discovery of a Novel Bromodomain and Extra Terminal Domain (BET) Protein Inhibitor, I-BET282E, Suitable for Clinical Progression.
AID656161Antiinflammatory activity in human THP1 cells2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.
AID1721368Inhibition of LPS-induced TNFalpha production in human whole blood preincubated for 30 mins followed by LPS addition and measured after overnight incubation by mesoscale assay2020Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17
GSK789: A Selective Inhibitor of the First Bromodomains (BD1) of the Bromo and Extra Terminal Domain (BET) Proteins.
AID1230000Displacement of FAM-labeled ZBA248 from BRD2 BD2 (349 to 460 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells after 30 mins by fluorescence polarization assay2015Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12
Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors.
AID705612Antiinflammatory activity in mouse endotoxaemia model assessed as protection against LPS-induced mortality at 10 mg/kg, iv administered 1 hr prior to LPS challenge measured up to 4 days2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).
AID705634Mutagenicity against Escherichia coli WP2uvrA by AMES test in absence of S9 fraction2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).
AID1666131Displacement of Alexa Fluor 647 labelled I-BET762 from N-terminal His6-tagged human BRDT BD2 (1 to 397 residues)/BD1 Y66A mutant expressed in Escherichia coli after 1 hr by TR-FRET assay2020Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17
Structure-Based Design of a Bromodomain and Extraterminal Domain (BET) Inhibitor Selective for the N-Terminal Bromodomains That Retains an Anti-inflammatory and Antiproliferative Phenotype.
AID1416021Cell cycle arrest in human MV4-11 cells assessed as accumulation at G2 phase after 24 hrs by propidium iodide staining-based flow cytometric method (Rvb = 11.98%)2017MedChemComm, Jun-01, Volume: 8, Issue:6
Discovery of novel trimethoxy-ring BRD4 bromodomain inhibitors: AlphaScreen assay, crystallography and cell-based assay.
AID1721411Antiproliferative activity against human MV4-11 cells after 72 hrs by cell titer glo assay2020Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17
GSK789: A Selective Inhibitor of the First Bromodomains (BD1) of the Bromo and Extra Terminal Domain (BET) Proteins.
AID656142Upregulation of ApoA1 expression in human HepG2 cells assessed as concentration required to increase 70% of luciferase activity after 18 hrs by luciferase reporter gene assay2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.
AID1784038Displacement of Alexa Fluor 647 labelled ligand from recombinant human N-terminal 6His-tagged BRD4-BD1 Y390A mutant (1 to 477 residue) expressed in Escherichia coli incubated for 30 mins by TR-FRET assay2021Journal of medicinal chemistry, 08-26, Volume: 64, Issue:16
Discovery of a Novel Bromodomain and Extra Terminal Domain (BET) Protein Inhibitor, I-BET282E, Suitable for Clinical Progression.
AID705646Intrinsic clearance in human liver microsomes assessed per mg of protein at 0.5 uM after 30 mins2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).
AID1666120Displacement of Alexa Fluor 647 labelled I-BET762 from N-terminal His6-tagged human BRD3 BD1 (1 to 435 residues)/BD2 Y348A mutant expressed in Escherichia coli after 1 hr by TR-FRET assay2020Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17
Structure-Based Design of a Bromodomain and Extraterminal Domain (BET) Inhibitor Selective for the N-Terminal Bromodomains That Retains an Anti-inflammatory and Antiproliferative Phenotype.
AID1535623Binding affinity to recombinant human N-terminal TEV-cleavable hexa-histidine tagged BRD4 bromodomain1 assessed as change in melting temperature at 30 uM measured after 30 mins by SYPRO orange dye based differential scanning fluorimetry2019Bioorganic & medicinal chemistry, 02-01, Volume: 27, Issue:3
Structure-guided discovery of a novel, potent, and orally bioavailable 3,5-dimethylisoxazole aryl-benzimidazole BET bromodomain inhibitor.
AID1196541Growth inhibition of human MV4-11 cells after 72 hrs by SRB assay2015Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3
Fragment-based drug discovery of 2-thiazolidinones as BRD4 inhibitors: 2. Structure-based optimization.
AID1535624Binding affinity to recombinant human N-terminal TEV-cleavable hexa-histidine tagged BRD4 bromodomain2 assessed as change in melting temperature at 30 uM measured after 30 mins by SYPRO orange dye based differential scanning fluorimetry2019Bioorganic & medicinal chemistry, 02-01, Volume: 27, Issue:3
Structure-guided discovery of a novel, potent, and orally bioavailable 3,5-dimethylisoxazole aryl-benzimidazole BET bromodomain inhibitor.
AID1196562Time dependent inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac substrate preincubated for 5 mins before NADPH addition and measured after 20 mins post NADPH addition2015Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3
Fragment-based drug discovery of 2-thiazolidinones as BRD4 inhibitors: 2. Structure-based optimization.
AID705631Mutagenicity against Salmonella typhimurium TA100 by AMES test in absence of S9 fraction2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).
AID1846027Inhibition of hedgehog signalling in mouse Shh Light II cells co-transfected with Gli firefly and Renilla-luciferase assessed as reduction in SAG-induced Gli luciferase activity incubated for 24 hrs by dual luciferase reporter assay2021European journal of medicinal chemistry, Apr-05, Volume: 215Medulloblastoma drugs in development: Current leads, trials and drawbacks.
AID772237Inhibition of BRD4 in human Raji cells assessed as reduction of MYC expression after 4 hrs2013ACS medicinal chemistry letters, Sep-12, Volume: 4, Issue:9
Discovery, Design, and Optimization of Isoxazole Azepine BET Inhibitors.
AID705614Half life in mouse2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).
AID1416028Induction of apoptosis in human MV4-11 cells assessed as necrotic cells after 72 hrs by annexin-V-FITC/propidium iodide staining-based flow cytometric method (Rvb = 0%)2017MedChemComm, Jun-01, Volume: 8, Issue:6
Discovery of novel trimethoxy-ring BRD4 bromodomain inhibitors: AlphaScreen assay, crystallography and cell-based assay.
AID705859Antiinflammatory activity in human whole blood assessed as inhibition of LPS-induced IFNgamma production2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).
AID1666133Selectivity index, difference between pIC50 for N-terminal His6-tagged human BRD3 BD1 (1 to 435 residues)/BD2 Y348A mutant expressed in Escherichia coli to pIC50 for N-terminal His6-tagged human BRD3 BD2 (1 to 435 residues)/BD1 Y73A mutant expressed in Es2020Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17
Structure-Based Design of a Bromodomain and Extraterminal Domain (BET) Inhibitor Selective for the N-Terminal Bromodomains That Retains an Anti-inflammatory and Antiproliferative Phenotype.
AID1230019Cytotoxicity against human MOLM13 cells harboring MLL1 fusion gene assessed as growth inhibition after 4 days by CellTiter-Glo luminescent assay2015Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12
Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors.
AID1230009Binding affinity to biotinylated CREBBP (1043 to 1159 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells by bio-layer interferometry method2015Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12
Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors.
AID1349420Inhibition of BRD4 in human MV4-11 cells assessed as downregulation of cMYC RNA expression by RNA-seq analysis2017ACS medicinal chemistry letters, Dec-14, Volume: 8, Issue:12
Design, Synthesis, and Biological Activity of 1,2,3-Triazolobenzodiazepine BET Bromodomain Inhibitors.
AID1230005Binding affinity to biotinylated BRD3 BD1 (24 to 144 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells by bio-layer interferometry method2015Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12
Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors.
AID656157Half life in CD rat2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.
AID705635Mutagenicity against Salmonella typhimurium TA1537 by AMES test in absence of S9 fraction2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).
AID1196555Inhibition of CYP3A4 in human liver microsomes at 10 uM preincubated for 5 mins before NADPH addition and measured after 20 mins post NADPH addition2015Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3
Fragment-based drug discovery of 2-thiazolidinones as BRD4 inhibitors: 2. Structure-based optimization.
AID1666117Displacement of Alexa Fluor 647 labelled I-BET762 from N-terminal His6-tagged human BRD2 BD2 (1 to 473 residues)/BD1 Y113A mutant expressed in Escherichia coli after 1 hr by TR-FRET assay2020Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17
Structure-Based Design of a Bromodomain and Extraterminal Domain (BET) Inhibitor Selective for the N-Terminal Bromodomains That Retains an Anti-inflammatory and Antiproliferative Phenotype.
AID656158Oral bioavailability in CD rat2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.
AID656156Volume of distribution at steady state in CD rat2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.
AID656160Bioactivation in rat hepatocytes assessed as glutathione trapping2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.
AID705620Volume of distribution in dog2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).
AID705650Time dependent inhibition of CYP2C192012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).
AID656159Bioactivation in human hepatocytes assessed as glutathione trapping2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.
AID705872Binding affinity to BRD3 assessed as inhibition of Alexa Fluor 488 binding after 60 mins by fluorescence anisotropic analysis2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).
AID1784034Inhibition of recombinant human CYP3A4 expressed in Escherichia coli using DEF as probe substrate incubated for 15 to 60 mins by fluorometric assay2021Journal of medicinal chemistry, 08-26, Volume: 64, Issue:16
Discovery of a Novel Bromodomain and Extra Terminal Domain (BET) Protein Inhibitor, I-BET282E, Suitable for Clinical Progression.
AID1416019Cell cycle arrest in human MV4-11 cells assessed as accumulation at G1 phase after 24 hrs by propidium iodide staining-based flow cytometric method (Rvb = 54.50%)2017MedChemComm, Jun-01, Volume: 8, Issue:6
Discovery of novel trimethoxy-ring BRD4 bromodomain inhibitors: AlphaScreen assay, crystallography and cell-based assay.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508612NCATS Parallel Artificial Membrane Permeability Assay (PAMPA) Profiling2017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
Highly predictive and interpretable models for PAMPA permeability.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508591NCATS Rat Liver Microsome Stability Profiling2020Scientific reports, 11-26, Volume: 10, Issue:1
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1345662Human bromodomain containing 2 (Bromodomain kinase (BRDK) family)2011Nature, Oct-02, Volume: 478, Issue:7370
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia.
AID1346122Human bromodomain containing 3 (Bromodomain kinase (BRDK) family)2011Nature, Oct-02, Volume: 478, Issue:7370
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia.
AID1345665Human bromodomain containing 4 (Bromodomain kinase (BRDK) family)2011Nature, Oct-02, Volume: 478, Issue:7370
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia.
AID1802212AlphaScreen BRD Binding Assay from Article 10.1038/nchembio.2209: \\Design and characterization of bivalent BET inhibitors.\\2016Nature chemical biology, Dec, Volume: 12, Issue:12
Design and characterization of bivalent BET inhibitors.
AID977608Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2011Nature, Oct-02, Volume: 478, Issue:7370
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (108)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's83 (76.85)24.3611
2020's25 (23.15)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 15.01

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index15.01 (24.57)
Research Supply Index4.71 (2.92)
Research Growth Index4.54 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (15.01)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.92%)5.53%
Reviews3 (2.75%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other105 (96.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]